ICYMI, some of this week’s featured content includes an exclusive interview about the iPLEDGE program issues, and articles on FDA approval of upadacitinib for psoriatic arthritis, ruxolitinib cream receiving Priority Review from the FDA for vitiligo, and more.
This letter to the editor in the Journal of the American Academy of Dermatology investigated how mental health and its association to race and ethnicity relate to patients with acne.
Arcutis Biotherapeutics has announced data suggesting that the vehicle in the investigational roflumilast cream had similar moisturizing properties as a commercially marketed, dermatologist-recommended, ceramide-containing moisturizer in adults with mild eczema.
Shared insight from dermatologists on novel topical JAK inhibitor therapy being investigated as an option for patients with vitiligo.
Looking toward the future management of vitiligo, expert dermatologists close out their discussion on JAK inhibition and other novel therapy.
A study investigated the acceptability and validity of patient-reported outcome measures for adult acne, comparing them to the validated acne-specific quality-of-life measure.
In this month's Legal Eagle column, David J. Goldberg, MD, JD, discusses why sexual assault complaints must be made public, even if the defendant is found not guilty.
Physicians and their teams have been unable to access the iPLEDGE site during an update to incorporate an FDA-approved modification to the iPLEDGE REMS that took effect December 13, 2021.
In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, explores scalp flaking causes and treatments.
In this week’s Pointers with Dr Portela, the 208SkinDoc explains the differences between lasers that can be used for various treatment goals.
Ruxolitinib cream (Opzelura; Incyte) receives priority review of its supplemental New Drug Application as a treatment for patients with vitiligo.
An expert details the ways to gain and retain new practice staff.
The FDA approves upadacitinib (Rinvoq; AbbVie) for the treatment of adult patients with active psoriatic arthritis.
The FDA grants Priority Review for spesolimab (BI655130; Boehringer Ingelheim) as a treatment for generalized pustular psoriasis.
Verrica Pharmaceuticals announced the FDA acceptance of the New Drug Application (NDA) resubmission for VP-102 (Verrica Pharmaceuticals) for the treatment of molluscum contagiosum.
In this video interview, Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/SGM Expert Resource Group, explains what happened with the iPLEDGE website.
A study in JAMA Dermatology dove into the subject of atopic eczema, investigating the patterns of activity that may continue into adulthood.
Klint Peebles, MD, FAAD, co-chair of the AAD LGBTQ/SGM Expert Resource Group, sits down with Dermatology Times® to discuss what changes were made to the iPLEDGE platform, examples of how the roll out has been unsuccessful, and how patients should be wary of trying to take old medications.
A recent study investigated practical issues related to the use of dupilumab for atopic dermatitis.
John Barbieri, MD, MBA, FAAD, speaking in his capacity as a member of the AADA iPLEDGE Workgroup, talks with Dermatology Times® about the recent iPLEDGE website struggles and guidance on how dermatologists should handle the situation.
Experts detail 5 tips to ask a financial advisor so they can best serve your interests.
A study investigated pulsed dye laser-mediated photodynamic therapy compared to conventional PDT for actinic keratosis.
A recent study evaluated reflective confocal microscopy for actinic keratosis treated with 5-aminolevulinic acid photodynamic therapy.
This episode of The Cutaneous Connection podcast, sponsored by Incyte, explores the world of vitiligo. From symptoms to current treatment dissatisfaction and the latest research, Pearl Grimes, MD, FAAD, explains where we are now with this pigmentary disorder and where we are headed.